Olema Oncology, Inc. (OLMA): who owns it and who trades it
As of Nov 16, 2026, OLMA insiders reported 25 open-market sales worth $24.7M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ian T Clark (Director), with $7.9M.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, OLMA insiders reported $0 of open-market purchases and $24.7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 24, 2026 | Cyrus Harmon | Director | Sale | 12,500 | $11.71 | $146K | Form 4 |
| Jul 23, 2026 | Cyrus Harmon | Director | Sale | 12,500 | $11.58 | $145K | Form 4 |
| Mar 4, 2026 | Shawnte Mitchell | CHIEF LEGAL OFFICER | Sale | 233 | $24.69 | $5.8K | Form 4 |
| Mar 4, 2026 | Shawnte Mitchell | CHIEF LEGAL OFFICER | Sale | 24,767 | $24.25 | $601K | Form 4 |
| Mar 3, 2026 | Shawnte Mitchell | CHIEF LEGAL OFFICER | Sale | 15,000 | $23.01 | $345K | Form 4 |
| Jan 20, 2026 | Cyrus Harmon | Director | Sale | 10,000 | $26.88 | $269K | Form 4 |
| Jan 15, 2026 | Shane William Charles Kovacs | CH. OPERATING & FINANCIA | Sale | 100,000 | $28.73 | $2.9M | Form 4 |
| Jan 14, 2026 | Cyrus Harmon | Director | Sale | 3,489 | $29.12 | $102K | Form 4 |
| Jan 14, 2026 | David C. Myles | CH. DISCOV. & NON-CLIN D | Sale | 14,997 | $28.60 | $429K | Form 4 |
| Jan 14, 2026 | David C. Myles | CH. DISCOV. & NON-CLIN D | Sale | 35,003 | $28.99 | $1M | Form 4 |
| Jan 13, 2026 | Shane William Charles Kovacs | CH. OPERATING & FINANCIA | Sale | 3,822 | $28.01 | $107K | Form 4 |
| Jan 13, 2026 | David C. Myles | CH. DISCOV. & NON-CLIN D | Sale | 49,800 | $27.60 | $1.4M | Form 4 |
| Jan 13, 2026 | David C. Myles | CH. DISCOV. & NON-CLIN D | Sale | 200 | $28.49 | $5.7K | Form 4 |
| Jan 12, 2026 | David C. Myles | CH. DISCOV. & NON-CLIN D | Sale | 10,000 | $28.34 | $283K | Form 4 |
| Dec 23, 2025 | Naseem Zojwalla | Chief Medical Officer | Sale | 99,509 | $27.66 | $2.8M | Form 4 |
| Dec 22, 2025 | Cyrus Harmon | Director | Sale | 2,881 | $28.53 | $82.2K | Form 4 |
| Dec 22, 2025 | Naseem Zojwalla | Chief Medical Officer | Sale | 100,000 | $28.04 | $2.8M | Form 4 |
| Dec 19, 2025 | Ian T Clark | Director | Sale | 29,904 | $28.83 | $862K | Form 4 |
| Dec 19, 2025 | Ian T Clark | Director | Sale | 193,056 | $29.71 | $5.7M | Form 4 |
| Dec 19, 2025 | Ian T Clark | Director | Sale | 41,840 | $30.48 | $1.3M | Form 4 |
| Dec 19, 2025 | David C. Myles | CH. DISCOV. & NON-CLIN D | Sale | 6,046 | $31.39 | $190K | Form 4 |
| Dec 19, 2025 | David C. Myles | CH. DISCOV. & NON-CLIN D | Sale | 43,729 | $30.40 | $1.3M | Form 4 |
| Dec 19, 2025 | David C. Myles | CH. DISCOV. & NON-CLIN D | Sale | 1,225 | $28.08 | $34.4K | Form 4 |
| Dec 19, 2025 | Naseem Zojwalla | Chief Medical Officer | Sale | 57,079 | $28.03 | $1.6M | Form 4 |
| Dec 19, 2025 | Naseem Zojwalla | Chief Medical Officer | Sale | 12,921 | $28.93 | $374K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ian T Clark | Director | – | $7.9M | Dec 19, 2025 |
| Naseem Zojwalla | Chief Medical Officer | – | $7.5M | Dec 23, 2025 |
| David C. Myles | CH. DISCOV. & NON-CLIN DEV OFF | – | $4.7M | Jan 14, 2026 |
| Shane William Charles Kovacs | CH. OPERATING & FINANCIAL OFF. | – | $3M | Jan 15, 2026 |
| Shawnte Mitchell | CHIEF LEGAL OFFICER | – | $952K | Mar 4, 2026 |
| Cyrus Harmon | Director | – | $744K | Jul 24, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
OLMA short interest
High short interest. 19.6% of OLMA shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 48%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 17.12M OLMA shares were sold short, 19.6% of the shares outstanding, up 9.2% from the report before. At the average daily volume of 1.44M shares, buying them all back would take about 11.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 17.12M | 19.57% | +9% | 1.44M | 11.9 |
| Oct 15, 2026 | 15.68M | 17.92% | +7% | 1.17M | 13.4 |
| Sep 30, 2026 | 14.70M | 16.80% | -9% | 1.44M | 10.2 |
| Sep 15, 2026 | 16.07M | 18.36% | +3% | 1.01M | 15.9 |
| Aug 31, 2026 | 15.66M | 17.90% | -1% | 845,052 | 18.5 |
| Aug 14, 2026 | 15.81M | 18.07% | -1% | 1.11M | 14.2 |
| Jul 31, 2026 | 15.96M | 18.32% | +6% | 876,854 | 18.2 |
| Jul 15, 2026 | 15.10M | 17.33% | +8% | 1.34M | 11.3 |
| Jun 30, 2026 | 14.03M | 16.10% | +9% | 2.47M | 5.7 |
| Jun 15, 2026 | 12.84M | 14.74% | +8% | 1.63M | 7.9 |
| May 29, 2026 | 11.93M | 13.69% | +3% | 1.13M | 10.5 |
| May 15, 2026 | 11.59M | 13.30% | -11% | 1.13M | 10.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Olema Oncology company events
Olema Oncology filed 15 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Oct 15, 2026LeadershipDr. Gorjan Hrustanovic notified Olema Pharmaceuticals, Inc. of his decision to resign from the Company’s Board of Directors, effective October 14, 2026. Filing
- Aug 13, 2026LeadershipOlema Pharmaceuticals, Inc. announced the appointment of Jason O’Byrne as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, which was approved by the Board of Directors of the Company on July 28, 2026 and effective as of August 11, 2026. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jun 23, 2026VoteReported shareholder vote results. Filing
- May 26, 2026AnnouncementAs described above, on May 26, 2026, the Company announced that it had entered into the Agreement with Bayer. Filing
- May 21, 2026AnnouncementAs described above, on May 21, 2026, the Company announced preliminary clinical data from its Phase 1 study of OP-3136. Filing
- May 12, 2026ResultsReleased financial results. Filing
- May 1, 2026AgreementOlema Pharmaceuticals, Inc. entered into a lease agreement with KR Oyster Point II, LLC, a Delaware limited liability company, pursuant to which the Company will lease an aggregate of approximately 38,176 square feet, consisting of 25,048 square feet of space located on the fourth floor and 13,128… Filing
- Apr 29, 2026LeadershipUpon recommendation from the Nominating and Corporate Governance Committee of the Board of Directors of Olema Pharmaceuticals, Inc., the Board appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026. Filing
- Mar 16, 2026ResultsReleased financial results. Filing
- Jan 30, 2026LeadershipOlema Pharmaceuticals, Inc. announced that Shane Kovacs, the Company’s Chief Operating and Financial Officer, is departing the Company effective January 30, 2026 to pursue new opportunities. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Nov 19, 2025AnnouncementOlema Pharmaceuticals, Inc. entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters named therein, relating to the issuance and sale in a public offering of 10,000,000 shares of the Company’s common stock, par value $0.0001 per share, at a… Filing
- Nov 18, 2025AnnouncementThe Company terminated the prospectus related to the sale of its common stock, $0.0001 par value per share in an “at-the-market” offering pursuant to the terms of the Sales Agreement, dated January 6, 2025, by and between the Company and TD Securities (USA) LLC. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Olema Oncology financials
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named OLMA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 7.2% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 7.2% |
| Oct 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13D/A | 6.6% |
| Oct 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13D/A | 6.6% |
Questions about Olema Oncology, Inc. (OLMA) stock
Are OLMA insiders buying or selling?
In the last 12 months, OLMA insiders reported no open-market purchases and 25 sales worth $24.7M. The latest trade was on Jul 24, 2026. See every trade.
What is the short interest in OLMA?
As of Oct 30, 2026, 17.12M OLMA shares were sold short, 19.6% of the shares outstanding, up 9.2% from the report before. At the average daily volume of 1.44M shares, buying them all back would take about 11.9 trading days (days to cover). See the history.
Executive pay
Olema Oncology's chief executive was paid a total of $3.2M for the year ended Dec 31, 2025, down 61% from $8.1M the year before. In the last 12 months, Olema Oncology's executives and directors bought no stock on the open market and sold $24.7M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.